# Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Canonical URL: https://biopharmsignal.com/news/BNTC/benitec-biopharma-releases-third-quarter-2026-financial-results-and-provides-operational-update
Ticker: BNTC
Company: Benitec Biopharma
Source: Benitec Biopharma
Published: 2026-05-14 12:00 EST
Original Source URL: https://www.benitec.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-14 12:00 EST — [Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update](https://biopharmsignal.com/news/BNTC/benitec-biopharma-releases-third-quarter-2026-financial-results-and-provides-operational-update) — Source: Benitec Biopharma
- 2026-04-28 11:00 EST — [Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting](https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b-2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting) — Source: Benitec Biopharma
- 2026-03-10 11:00 EST — [Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)](https://biopharmsignal.com/news/BNTC/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-for-oculopharyngeal-muscular-dystrophy-opmd) — Source: Benitec Biopharma
- 2026-03-09 11:00 EST — [Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference](https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-positive-interim-phase-1b-2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference) — Source: Benitec Biopharma
- 2026-02-23 12:00 EST — [Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference](https://biopharmsignal.com/news/BNTC/benitec-biopharma-announces-acceptance-of-late-breaking-abstract-for-the-bb-301-phase-1b-2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference) — Source: Benitec Biopharma
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)